Cogent Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Cogent Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-22.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-22.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Sep 04

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

May 22

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Mar 05

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 18

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 10

Cogent Biosciences names new chief legal officer

May 03

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Mar 17

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

Dec 23

Cogent Biosciences prices upsized $100M equity offering

Dec 02

Cogent Bio launches $60M equity offering, shares down 7%

Nov 30

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Nov 18

Cogent Biosciences EPS misses by $4.91

Nov 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: COGT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: COGT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cogent Biosciences Piyasaya Karşı Temettü Getirisi

COGT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (COGT)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (COGT) (3 yıla kadar)	0%

Önemli Temettü: COGT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, COGT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: COGT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: COGT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cogent Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences Announces Phase 3 Peak Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis

Cogent Biosciences: Inflection Year Directly Ahead

Cogent Biosciences, Inc. Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis

Cogent Biosciences, Inc. Announces Positive Updated Lead-In Data from Ongoing Phase 3 Peak Trial Evaluating Bezuclastinib in Patients with Gastrointestinal Stromal Tumors at ASCO Annual Meeting

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 7.5% to US$17.00

Cogent Biosciences, Inc., Annual General Meeting, Jun 05, 2024

Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

New major risk - Share price stability

Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis

Price target decreased by 18% to US$18.40

Cogent Biosciences, Inc. Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Cogent Biosciences, Inc. Announces Positive Lead-In Data from Its Ongoing Phase 3 Peak Trial Evaluating the Selective KIT D816V in Patients with Gastrointestinal Stromal Tumors

High number of new directors

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences, Inc Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences, Inc. Appoints Rachael Easton, VP, Head of Clinical Development

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences: What's Ahead

Price target increased to US$19.43

Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 2000 Growth Index

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Cogent Biosciences, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 2 Apex Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Price target decreased to US$18.17

High number of new and inexperienced directors

Cogent Biosciences, Inc. Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event

High number of new and inexperienced directors

Price target increased to US$21.43

Cogent Biosciences names new chief legal officer

CFO & Principal Accounting Officer recently sold US$158k worth of stock

Cogent Biosciences, Inc. Appoints Sara Saltzman as Senior Vice President of Regulatory Affairs

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Cogent Biosciences Appoints Todd E. Shegog to its Board of Directors

New 90-day low: US$8.59

New 90-day low: US$9.09

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

New 90-day high: US$13.01

Cogent Biosciences prices upsized $100M equity offering

Cogent Biosciences, Inc. Appoints Brad Barnett as Chief Technology Officer

Cogent Bio launches $60M equity offering, shares down 7%

Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Cogent Biosciences EPS misses by $4.91

New 90-day high: US$3.21

Cogent Biosciences, Inc Announces Executive Changes

Kiq Bio LLC acquired Unum Therapeutics Inc. (NasdaqGS:UMRX) in a reverse merger transaction.

Unum Therapeutics Inc. announced that it has received $104.39968 million in funding from a group of investors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin